Exchange Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.12M | Buy |
46,147
+39
| +0.1% | +$4.15K | 0.76% | 36 |
|
|
2025
Q1 | $5.17M | Sell |
46,108
-225
| -0.5% | -$23.2K | 0.84% | 35 |
|
|
2024
Q4 | $4.28M | Sell |
46,333
-294
| -0.6% | -$26.5K | 0.68% | 43 |
|
|
2024
Q3 | $3.91M | Buy |
46,627
+9,815
| +27% | +$749K | 0.62% | 50 |
|
|
2024
Q2 | $2.53M | Sell |
36,812
-628
| -2% | -$41.9K | 0.41% | 77 |
|
|
2024
Q1 | $2.74M | Buy |
37,440
+350
| +0.9% | +$26.9K | 0.45% | 73 |
|
|
2023
Q4 | $3M | Sell |
37,090
-650
| -2% | -$50.6K | 0.54% | 58 |
|
|
2023
Q3 | $2.83M | Buy |
37,740
+3,346
| +10% | +$257K | 0.53% | 59 |
|
|
2023
Q2 | $2.65M | Sell |
34,394
-65
| -0.2% | -$5.18K | 0.49% | 68 |
|
|
2023
Q1 | $2.86M | Buy |
34,459
+300
| +0.9% | +$24.8K | 0.58% | 61 |
|
|
2022
Q4 | $2.93M | Sell |
34,159
-855
| -2% | -$67.7K | 0.64% | 57 |
|
|
2022
Q3 | $2.16M | Sell |
35,014
-458
| -1% | -$28.9K | 0.5% | 68 |
|
|
2022
Q2 | $2.19M | Sell |
35,472
-225
| -0.6% | -$13.9K | 0.48% | 71 |
|
|
2022
Q1 | $2.12M | Sell |
35,697
-19
| -0.1% | -$1.22K | 0.4% | 80 |
|
|
2021
Q4 | $2.59M | Sell |
35,716
-30
| -0.1% | -$2.07K | 0.47% | 70 |
|
|
2021
Q3 | $2.5M | Buy |
35,746
+1,681
| +5% | +$118K | 0.48% | 66 |
|
|
2021
Q2 | $2.35M | Buy |
34,065
+3,296
| +11% | +$220K | 0.45% | 71 |
|
|
2021
Q1 | $1.99M | Buy |
30,769
+3,570
| +13% | +$230K | 0.41% | 76 |
|
|
2020
Q4 | $1.58M | Buy |
27,199
+12,763
| +88% | +$770K | 0.35% | 82 |
|
|
2020
Q3 | $912K | Buy |
14,436
+1,766
| +14% | +$122K | 0.23% | 106 |
|
|
2020
Q2 | $975K | Buy |
12,670
+150
| +1% | +$11.5K | 0.27% | 97 |
|
|
2020
Q1 | $936K | Buy |
+12,520
| New | +$865K | 0.31% | 87 |
|
|
2018
Q4 | – | Sell |
-200
| Closed | -$15K | – | 179 |
|
|
2018
Q3 | $15K | Buy |
+200
| New | +$15.1K | ﹤0.01% | 216 |
|
|
2018
Q1 | – | Sell |
-55
| Closed | -$4K | – | 260 |
|
|
2017
Q4 | $4K | Sell |
55
-75
| -58% | -$5.7K | ﹤0.01% | 209 |
|
|
2017
Q3 | $11K | Sell |
130
-80
| -38% | -$6.12K | ﹤0.01% | 195 |
|
|
2017
Q2 | $15K | Buy |
210
+80
| +62% | +$5.32K | 0.01% | 164 |
|
|
2017
Q1 | $9K | Sell |
130
-110
| -46% | -$7.74K | ﹤0.01% | 175 |
|
|
2016
Q4 | $17K | Sell |
240
-38,542
| -99% | -$2.86M | 0.01% | 132 |
|
|
2016
Q3 | $3.07M | Sell |
38,782
-562
| -1% | -$45.7K | 1.21% | 31 |
|
|
2016
Q2 | $3.28M | Buy |
39,344
+868
| +2% | +$77K | 1.33% | 29 |
|
|
2016
Q1 | $3.53M | Sell |
38,476
-248
| -0.6% | -$22.4K | 1.52% | 25 |
|
|
2015
Q4 | $3.92M | Buy |
38,724
+306
| +0.8% | +$31.8K | 1.66% | 25 |
|
|
2015
Q3 | $3.77M | Buy |
38,418
+357
| +0.9% | +$39.6K | 1.75% | 21 |
|
|
2015
Q2 | $4.46M | Buy |
38,061
+145
| +0.4% | +$15.8K | 1.82% | 20 |
|
|
2015
Q1 | $3.72M | Buy |
37,916
+36,918
| +3,699% | +$3.75M | 1.52% | 29 |
|
|
2014
Q4 | $95K | Buy |
+998
| New | +$103K | 0.04% | 90 |
|
Other funds holding GILD
Exchange Capital Management's GILD Position: Q2 2025 in Review
Exchange Capital Management increased its Gilead Sciences (GILD) stake by 0.08% in Q2 2025, buying an estimated $4.15K and bringing the position to 46,147 shares worth $5.12M. The position accounts for 0.76% of the portfolio, ranked #36.
Exchange Capital Management first reported a position in GILD in Q4 2014 and has held it in 36 quarters since. The position peaked at $5.17M in Q1 2025. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.
- Exchange Capital Management held 46,147 shares of Gilead Sciences worth $5.12M as of Q2 2025.
- Exchange Capital Management bought 39 Gilead Sciences shares in Q2 2025, an estimated $4.15K.
- Gilead Sciences made up 0.76% of Exchange Capital Management's portfolio in Q2 2025, its #36 holding.
- Exchange Capital Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 36 quarters since.
- Exchange Capital Management's Gilead Sciences position peaked at $5.17M in Q1 2025.
- 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.
Based on Exchange Capital Management's 13F filing for Q2 2025, filed 21 Jul 2025.